Volume 13 Supplement 4
48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
© Arastéh et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Wk 24 TRANxITION study data showed patients transitioned from immediate release nevirapine (NVP IR) twice daily (BID) to NVP extended release (NVP XR) once-daily (QD) demonstrated non-inferior efficacy to patients continuing on IR NVP BID . Similar safety was reported for NVP XR and NVP IR in the VERxVE study 2. Wk 48 efficacy/safety data from TRANxITION study are presented here.
Open label, randomized (2:1), non-inferiority, parallel group study comparing NVP XR 400 mg QD with NVP IR 200 mg BID in HIV-1 patients >18 years receiving IR NVP plus one of three NRTI combinations, with viral load (VL) <50 copies/mL. Patients remained on their previous background therapy for treatment duration. Sustained virologic response (VL <50 copies/mL) was assessed at Wk 48 using a time-to-loss of virologic response (TLOVR) algorithm.
NVP XR QD (N=295)
IR NVP BID (N=148)
Difference (95% CI)
Virologic response (VL <50 copies/mL, TLOVR-FAS), n (%)
0.6 (-5.9, 7.1)*
CD4+ count cells/mm3 (LOCF), mean (SD)
AEs, n (%)
DAIDS Grade 3-4
SAEs, n (%)†
At Wk 48, non-inferiority between the NVP XR 400 mg QD and NVP IR 200 mg BID groups was sustained. No unexpected AEs were observed at Wk 48. These data support transition from NVP IR to NVP XR in patients stable on the former formulation.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.